CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Analyst Ratings
USA - NASDAQ:CNTA - US1523091007 - ADR
24.39 USD
+0.41 (+1.71%)
ChartMill assigns a Buy % Consensus number of 85% to CNTA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 33.49. This target is 37.31% above the current price.
CNTA was analyzed by 20 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CNTA.
In the previous month the buy percentage consensus was at a similar level.
CNTA was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-28 | Stephens & Co. | Initiate | Overweight |
| 2025-10-06 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-09-03 | Wells Fargo | Initiate | Overweight |
| 2025-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-30 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-21 | Truist Securities | Initiate | Buy |
| 2025-05-28 | Needham | Initiate | Buy |
| 2025-05-08 | Chardan Capital | Initiate | Buy |
| 2025-03-31 | Piper Sandler | Initiate | Overweight |
| 2025-03-26 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-10 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-01-07 | TD Cowen | Initiate | Buy |
| 2024-11-15 | Guggenheim | Maintains | Buy -> Buy |
| 2024-09-19 | B. Riley Securities | Initiate | Buy |
| 2024-09-19 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2024-09-16 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-09-11 | Guggenheim | Maintains | Buy -> Buy |
| 2024-09-11 | Jefferies | Maintains | Buy -> Buy |
| 2024-09-09 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-08-14 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-07-18 | Oppenheimer | Initiate | Outperform |
| 2024-06-21 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-04-01 | BMO Capital | Maintains | Outperform -> Outperform |
| 2023-11-15 | Jefferies | Upgrade | Hold -> Buy |
| 2023-10-26 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2023-08-15 | SVB Securities | Maintains | Outperform -> Outperform |
| 2023-08-15 | Guggenheim | Maintains | Buy -> Buy |
| 2023-08-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-07-25 | BMO Capital | Maintains | Outperform -> Outperform |
| 2023-06-21 | Evercore ISI Group | Initiate | Outperform |
CENTESSA PHARMACEUTICALS-ADR / CNTA FAQ
What do analysts expect the price target to be for CENTESSA PHARMACEUTICALS-ADR (CNTA)?
20 analysts have analysed CNTA and the average price target is 33.49 USD. This implies a price increase of 37.31% is expected in the next year compared to the current price of 24.39.
How do analysts rate CENTESSA PHARMACEUTICALS-ADR (CNTA)?
The consensus rating for CENTESSA PHARMACEUTICALS-ADR (CNTA) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for CNTA stock?
The number of analysts covering CENTESSA PHARMACEUTICALS-ADR (CNTA) is 20.